Citadel Advisors’s Cumberland Pharmaceuticals CPIX Stock Holding History

Citadel Advisors’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.6K	Sell	12,500 -16,500	-57%	-$63.6K	﹤0.01%	12485
2025 Q4	$115K	Buy	29,000 +7,700	+36%	+$22.8K	﹤0.01%	11524
2025 Q3	$66.5K	Buy	+21,300	New	+$70.8K	﹤0.01%	12063
2025 Q2	–	Sell	-6,800	Closed	-$28.8K	–	12859
2025 Q1	$28.8K	Buy	+6,800	New	+$28.2K	﹤0.01%	12862
2024 Q3	–	Sell	-200	Closed	-$306	–	14337
2024 Q2	$306	Hold	200	–	–	﹤0.01%	14036
2024 Q1	$336	Sell	200 -5,500	-96%	-$11K	﹤0.01%	14359
2023 Q4	$9.92K	Sell	5,700 -700	-11%	-$1.28K	﹤0.01%	13133
2023 Q3	$12.1K	Buy	6,400 +4,300	+205%	+$7.21K	﹤0.01%	12980
2023 Q2	$3.09K	Sell	2,100 -100	-5%	-$173	﹤0.01%	13722
2023 Q1	$4.29K	Buy	+2,200	New	+$5.23K	﹤0.01%	13966

Other funds holding CPIX

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors's CPIX Position: Q1 2026 in Review

Citadel Advisors reduced its Cumberland Pharmaceuticals (CPIX) stake by 24% in Q1 2026, selling an estimated $20.5K and leaving 16,643 shares worth $54.1K. The position accounts for ﹤0.01% of the portfolio, ranked #12375.

Citadel Advisors first reported a position in CPIX in Q2 2013 and has held it in 18 quarters since. The position peaked at $249K in Q2 2025. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2026.

Citadel Advisors held 16,643 shares of Cumberland Pharmaceuticals worth $54.1K as of Q1 2026.
Citadel Advisors sold 5,314 Cumberland Pharmaceuticals shares in Q1 2026, an estimated $20.5K.
Cumberland Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12375 holding.
Citadel Advisors first reported a position in Cumberland Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
Citadel Advisors's Cumberland Pharmaceuticals position peaked at $249K in Q2 2025.
29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.